Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268441 | 0.90 | GRM4 (0.31) | — | |
| SCHEMBL1269182 | 0.69 | TP53 (0.38) | TP53KMT2ATSHRPOLBNPSR1 | |
| SCHEMBL19994644 | 0.59 | MAOB (0.59) | OPRM1KMT2AMAOBTSHRALDH1A1 | |
| SCHEMBL16838790 | 0.58 | MAOB (0.63) | MAOB | |
| SCHEMBL14661913 | 0.58 | BRD4 (0.48) | KMT2APOLB | |
| SCHEMBL6272305 | 0.58 | KMT2A (0.53) | TP53KMT2ATSHRPOLBALDH1A1 | |
| SCHEMBL6267118 | 0.58 | NPC1 (0.59) | TP53KMT2APOLBALDH1A1 | |
| SCHEMBL4962234 | 0.57 | MAOB (0.53) | OPRM1KMT2AMAOBTSHRALDH1A1 | |
| SCHEMBL1710699 | 0.57 | ALDH1A1 (0.52) | KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL14862904 | 0.57 | MAOB (0.55) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | TP53 1224/4885OPRM1 4510/4885KMT2A 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.